Q1 FY27 results analysis · July 31, 2026

Mankind Pharma Q1 FY27 Results Analysis: EBITDA Margin Expands 249 bps, PAT Jumps 30%

+29.1%PAT year on year, Rs. 574.09 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Mankind Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 4,030.59 Cr (+12.89% YoY) and PAT growth of +29.12% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 30, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 4,030.59 Cr (+12.89% YoY)
PAT (Q1)Rs. 574.09 Cr (+29.12% YoY)
EBITDA margin26.30% (+249 bps YoY)
EPS (Q1)Rs. 13.76 (+29.57% YoY)
Market capRs. 106,383.63 Cr
CMPRs. 2,575.90

Quarter Snapshot

Mankind Pharma delivered strong Q1 FY27 results with consolidated revenue growing 12.89% YoY and EBITDA margin expanding 249 bps to 26.30%, driven by operating leverage and lower finance costs. PAT grew 29.60% despite a normalised tax rate. However, no management guidance is available, and the quarter included elevated inventory build-up and ongoing tax proceedings.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 12.89% YoY to Rs.4,030.59 crore.
  • Consolidated EBITDA margin expanded 249 bps YoY to 26.30%.
  • PAT (owners) grew 29.60% YoY to Rs.568.06 crore.
  • Finance costs declined 35.55% YoY to Rs.109.98 crore, aided by Rs.1,250 crore NCD redemption.
  • Other expenses grew only 8.58% YoY, below revenue growth of 12.89%.
  • No exceptional items in Q1 FY27, simplifying earnings comparison.

Risk Factors

  • Effective tax rate normalised to 25.39% from 17.74% YoY, reducing net profit growth.
  • OCI recorded a net loss of Rs.20.31 crore, driven by negative exchange differences on foreign operations.
  • Subsidiary contribution to PAT declined sharply from Rs.23.05 crore in Q1 FY26 to Rs.9.57 crore in Q1 FY27.
  • Income tax proceedings of Rs.1,908.66 crore outstanding, with emphasis of matter in audit report.
  • Inventory build-up of Rs.133.86 crore (consolidated) indicates working capital investment, likely from BSV integration.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.